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Assessment of total and divided renal plasma flow by 1231-hippu-
ran renography. We studied 23 patients with suspected renal hy-
pertension, including 12 with renal artery stenosis, or occlusion.
Total effective renal plasma flow (ERPF) was measured in all
patients by conventional p-aminohippurate (PAH) clearance and
by 1231-hippuran clearance performed on the same day. A close
correlation between the two techniques was obtained (r = 0.87,
P < 0.001) with the latter technique underestimating the former
by a mean ratio of 0.89:1.00. We describe a technique for deriv-
ing ERPF for individual kidneys by '231-hippuran renography,
and the data obtained by this method correlate well with data
obtained from bilateral ureteric catheterization studies (r 0.76,
P < 0.001 for both affected and unaffected sides) in 17 patients.
The renographic technique is particularly accurate in quan-
titating ERPF in the 12 patients with renal artery stenosis, and is
recommended as the investigation of choice in the assessment of
ERPF in patients with this condition.
Evaluation des debits plasmatiques rénaux total et séparés au
moyen de Ia rénographie au '231-hippuran. Vingt trois malades
ayant une hypertension d'origine rénale présumée, incluant 12
sténoses ou occlusions d'artêres rénales, ont été étudiCs. Le dé-
bit plasmatique renal total effectif (ERPF) a été niesuré chez
tous les malades par la clearance du para-aminohippurate (PAH)
et par Ia clearance du 1231-hippuran réalisées le mCme jour. Une
correlation étroite entre les deux techniques a etC observCe (r =
0,87; P < 0,001), celle de l'hippuran Ctant infCrieure a celle du
PAH d'un facteur 0,89:1,00. Une technique d'Cvaluation d'
ERPF de chaque rein au moyen de la rCnographie au '231-hippu-
ran est décrite. Les valeurs obtenues par cette mCthode sont
bien corrClCes avec celles fournies par Ia cathCtCrisation ur-
CtCrale bilatdrale (r = 0,76; P <0,001) chez 17 malades. Ii est
apparu que Ia technique rénographique est particulièrement pré-
cise pour l'évaluation d'ERPF chez 12 malades atteints de sté-
nose de l'artCre rCnale. Elle est recommandCe comme investiga-
tion de choix dans l'évaluation d'ERPF chez les malades ayant
ce type d'atteinte.
Assessment of individual renal function is impor-
tant in the investigation of a hypertensive patient in
whom a renal cause is suspected and in whom the
possibility of surgical intervention arises [1]. This
can be made accurately by bilateral ureteric cathe-
terization ("split" or divided renal function) studies
[I], but the disadvantages of the technique, particu-
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larly the labor involved and its invasiveness, have
discouraged its continued widespread use [2, 3]. So-
dium '311-orthoiodohippurate ("hippuran") renog-
raphy has been one alternative method widely used
for several years to determine total renal function
[4, 5], but accurate comparisons of divided renal
function assessed by renography and by bilateral
ureteric catheterization studies are lacking in man.
Recently, 1231-labeled hippuran has become avail-
able [6, 7]. This allows larger activities to be given
safely for the imaging of kidney function and results
in greater accuracy of quantitation. In the present
study, 1231-hippuran renography was used to assess
total effective renal plasma flow (ERPF) and indi-
vidual ERPF to each kidney in patients with sus-
pected renal hypertension. These results were com-
pared with the results of bilateral ureteric catheteri-
zation studies and conventional overall para-
aminohippurate (PAH) and creatinine clearance.
Methods
Patients. We studied 23 patients: 12 were female
(age range, 16 to 55 years; mean, 37 years) and 11
were male (age range, 15 to 56; mean, 39 years). All
had diastolic blood pressures (Vth phase) of 100 mm
Hg or more while recumbent at a first visit to the
outpatient clinic. Twelve patients had arteri-
ographic evidence of unilateral renal artery disease
(7 had atheromatous stenosis of a main renal artery,
2 had the typical beaded appearance of fibromuscu-
lar hyperplasia [8], and 3 had occlusion of a main
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renal artery). In 2 further patients with suspected
renal artery stenosis, no arteriographic abnormality
of the renal vessels was demonstrated. Five pa-
tients had parenchymal renal disease (Table 1), 2
had unilateral small kidney of undetermined aetiol-
ogy, one had congenital absence of one kidney, and
one had had an ischemic kidney removed alter oc-
clusion of a renal artery.
Each of the 23 patients underwent 1231-hippuran
renography and conventional PAH and creatinine
clearance measurements on the same day. Seven-
teen patients had undergone bilateral ureteric cathe-
terization studies on a previous occasion, a mean of
4 months before renography (range, 1 day to 17
months).
'231-hippuran renography. Sodium 1231-hippuran
(The Atomic Energy Research Establishment, Har-
well) was prepared by the copper sulphate method
first described by Wanek, Huph, and O'Brien [9],
and later modified by Herman et at [101. Renal im-
ages were recorded and analyzed with a large-field-
of-view gamma camera (Nuclear Enterprises) con-
nected to a computer (Varian V-76) with a color
television display. Each patient was positioned
prone beneath the gamma camera with the kidneys
central in the field of view. Following an i.v. bolus
injection of 1 mCi of 1231-hippuran, forty 30-sec im-
ages were recorded. Water loading of patients was
avoided during the study. No patients were taking
drugs, such as antibiotics or probenecid [11, 12],
that might have competed with iodo-hippuran at the
transport sites in the proximal renal tubules.
In the subsequent analysis, all the images were
first summed to provide a well-defined image for se-
lection of regions of interest for quantification. Five
regions were selected, as shown in Fig. 1. An activi-
ty/time curve was then calculated for each region by
using the sequential data from this series of images.
Variations in gross kidney activity were provided
by the curves obtained from regions 1 and 2. The
net variations in kidney activity were obtained by
substracting the background variation observed in
regions 1A and 2A surrounding each kidney from
the gross activity variation after normalization for
the different areas in each case; that is,
k(t) = K(t) — cb(t)
where k(t) is the net kidney count, K(t) is the gross
kidney count, b(t) is the count in the background
area, and c is the normalizing factor (kidney area ÷
background area—for example, area of region 1
area of region lA). The selection of the area sur-
rounding the kidney as representing the background
to kidney activity has been validated by Short et al
[13] using nephrectomy sites. The technique has al-
so been used by Piepz, Dobbeleir, and Erbsmann
[14] in the study of the clearance of 99mTc-DTPA.
Region 3 superior to the kidneys was taken solely
as an area of vascular activity to assess the varia-
tion of blood activity with time. The activity in this
Fig. 1. 1231-hippuran renogram showing the regions of interest for quantitative analysis. Regions 1 and 2 are kidney regions; regions la
and 2a are perirenal background areas; region 3 is area of vascular activity.
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area has been shown to represent the blood clear-
ance of hippuran [13].
The blood background curve, together with the
activity of a peripheral venous blood sample (10 ml)
obtained between 10 and 15 mm after injection of
the isotope, was used to calculate the total ERPF in
the manner described by Ram, Evans, and Chis-
holm [15]. The rectilinear part of a logarithmic/lin-
ear plot of the vascular activity curve between 10
and 20 mm after dose administration was extrapo-
lated back to zero time. The change between the
time of the plasma sample and zero time was then
used to correct proportionately the measured
sample plasma activity back to zero time. The total
ERPF (min1) was then calculated by the formula
ERPF =
p(o)
where x is the slope of the vascular activity curve
(as above) (counts . min1), D is the activity in the
given dose (counts . sec'), and p(o) is the plasma
activity (counts. sec1) at time zero. The activity in
the plasma sample and in a known aliquot of the
given dose was counted with the same geometry in
a well-type scintillation counter and scaler.
The ratio of the effective plasma flows to each
kidney was determined by an extension of the math-
ematic model first devised by Britton and Brown
[16]. The model describes the renogram curve dur-
ing the stage of increasing renal activity before ex-
cretion of hippuran into the renal pelvis takes place.
The total net kidney activity, k(t), is given by
k(t) = ERPF B(t)
where B(t) is the integrated kidney background ac-
tivity that is assumed to follow the concentration of
hippuran presented to the kidneys.
The original expression has been slightly sim-
plified by assuming that the hippuran arrives simul-
taneously at the kidney and the kidney background
regions on each side. This model has been used pre-
viously by Brodkey, Schlegel, and Derouen [12] to
calculate the total ERPF. In the present study, it
has been assumed that for the two kidneys
kL(t) = ERPFL BL(t)
and kR(t) ERPFR• BR(t)
where the subscripts L and R refer to the left and
right kidneys, respectively. In each kidney, the in-
dividual ERPF can therefore be derived from the
slope of a linear relationship between k(t) and B(t).
The ratio of the plasma clearance is then given by
ERPFL
—
kL(t)/BL(t)
ERPFR kR(t)/BR(t)
To determine the slopes experimentally, we
graphed the values of net kidney activity against the
integrated kidney background activity for each im-
age in the period 0.5 to 2.5 mm after administration
of hippuran. The first 0.5 mm was excluded to en-
sure that the kidney background was proportional
to the blood concentration of hippuran, as de-
scribed by Holroyd, Chishoim, and Glass [17]. In all
studies, the peak of the kidney activity curve was
reached after 2.5 mm, and the applicability of the
analysis to the phase before hippuran excretion
would appear to be valid. Regression lines were fit-
ted to the data for each kidney by the method of
least squares and the slopes noted. The ratio of the
individual ERPF's was taken as the ratio of the two
slopes.
PAH and creatinine clearances. Total renal func-
tion was assessed on the day of renography in all
patients. Following a loading dose of 0.035 mllkg of
20% PAH (amino-hippurate, Merck Sharp &
Dohme), an infusion of 2.65 ml of 20% PAH in 500
ml of 10% mannitol was begun at 10 mllmin and
continued throughout a 30-mm run-in period and
three 30-mm urine collections periods. Plasma sam-
ples for PAH and creatinine concentration were ob-
tained midway through each collection period.
Urine samples were passed spontaneously without
catheterization. Plasma and urine PAH concentra-
tions were measured according to the method of
Waugh and Beall [18].
Bilateral ureteric catheterization studies. Bilater-
al ureteric catheterization studies (BUCS) following
spinal anaesthesia were performed in 17 patients by
a modification of the technique described by Brown
et al [19], with diuresis being induced and main-
tained by i.v. mannitol infusion in addition to oral
water loading rather than by oral water loading
alone. PAH was infused in the mannitol in a manner
identical to that described above for assessment of
total renal function. Simultaneous collections of
urine from both ureters and bladder (the latter to
detect leakage of urine past ill-fitting ureteral cath-
eters—an event that occurred in only one of our pa-
tients, see Table 3) allowed accurate quantitation
for each kidney of urine flow rate, urine sodium
concentration, creatinine concentration, and PAH
concentration. Peripheral plasma samples, obtained
midway through each of three sequential timed
urine collection periods and assayed for creatinine
and PAH concentration, allowed values for creati-
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nine clearance (Ce,) and PAH clearance (CPAH) to be
derived for each kidney.
Results
Total clearance by both kidneys. Total clearance
measurements obtained by the three techniques are
presented in Table 1 and compared in Table 2.
1231-hippuran clearance and conventional PAH
clearance (CPAH) on the same day correlate closely
(Fig. 2; r = 0.87). But, as shown by the regression
equation in Fig. 2, results obtained by the former
technique tend to be lower than those obtained by
the latter. This well-recognized phenomenon [20] is
reflected in the mean (± 1 SD) value for CPAH of 346
184 mllmin, which is significantly different from
the mean hippuran clearance of 299 167 mllmin
(paired t =
—2.46, P < 0.05). The ratio of hippuran
clearance to CPAH in this study is 0.89 0.19 (mean
1 SD).
'231-hippuran clearance and total CPAH measured
at BUCS also correlate well (Fig 2; r = 0.76). Any
change in renal function between the time of BUCS
and renography was not statistically significant
(comparison of means by Student's t test), with
creatinine clearance falling from 70 25 to 65 22
mllmin and CPAH falling from 366 168 to 325 187
mi/mm. Again in agreement with previous experi-
ence [20], hippuran clearance values were signifi-
cantly lower than CPAH values (N = 17, mean CPA1I
of 366 168 mllmin, mean hippuran clearance of
297 187 mllmin, paired t =
—2.30, P < 0.05).
Table 1. Clinical features and PAH and hippuran clearance valuesa
Total clearance
mi/mm
CPAR Hippuran clearance
Age CPAH on day of by '231-hippuran
Patient Sex yr Diagnosis at BUCS renogram renography
I M 41 Renal artery stenosis 114 115 122
2 F 33 Renal artery steno sis (FMH) 494 339 433
3 M 56 Renal artery stenosis 183 144 123
4 F 27 Renal artery steno sis 259 265 202
5 M 42 Renal artery stenosis 664 420 371
6 M 29 Renal artery stenosis 571 565 686
7 F 46 Renal artery stenosis (FMH) 543 305 265
8 M 54 Renal artery stenosis 441 256 271
9 F 52 Renal artery stenosis 150 73 83
10 M 16 Renal artery occlusion 567 837 740
11 M 49 Renal artery occlusion 242" 200 176
12 F 55 Renal artery occlusion ND 172 131
13 F 40 Small kidney ? etiology 294 273 273
14 F 52 Small kidney ? etiology 285 222 210
15 F 18 Pyelonephritis, small kidney 299 355 375
16 F 18 Ischemic damage 348 490 187
17 M 34 Essential hypertension 527 442 354
18 M 42 Postnephrectomy 247b 223 185
19 M 36 Cystine stones, unilateral
function
ND 418 308
20 F 40 Hypernephroma ND 665 427
21 F 16 Absent L. kidney (congenital) ND 342 260
22 M 29 Glomerulonephritis ND 299 251
23 F 43 Abdominal bruit ND 533 450
Meanvalues SD 366 168(N = 17) 346 184(N 23) 299 167(N = 23)
a Abbreviations used are FMH, fibromuscular hyperplasia; ND, not done; BUCS, bilateral ureteric catheterization studies.
"Clearance of PAH at split function studies is taken as that for the kidney which remains functional at the time of renography.
Table 2. Correlation of clearance techniques, all patients
Ordinate a Abscissa N Regressionequation
Correlation
coefficient P
CPAL, conventional (day of renogram) Hippuran clearance 23 y = 0.95x + 60 0.87 <0.001
CPAHbYBUCS CPAH, conventional (day of renogram) 17 y = 0.67x + 149 0.74 <0.001
CPAHbYBUCS Hippuran clearance 17 y = 0.69x + 161 0.76 <0.001
a BUCS is bilateral ureteric catheterization studies.
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200 300 400 500 600
Hippuran clearance, mi/mm
Fig. 2. Upper panel. Comparison of PAH clearance at divided
studies with 1231-hippuran clearance. Lower panel. Comparison
of total PAH clearance on the day of renography with 1231-hippu-
ran clearance. Closed circles represent cases of renal artery ste-
nosis. Open squares represent the other case of suspected renal
hypertension (Table I).
Using the same chemical technique for measure-
ment of PAH [18], we found that the CPAH values on
the day of renography and at BUCS correlate well
(Table 2; r = 0.74) and that the mean values, report-
ed above, are not significantly different (N = 17, t =
1.33, P = 0.2). It may be seen from Table I that the
two CPAH estimations correlate more closely at
lower values, whereas at higher values the CPAH ob-
tained on the day of renography appears to be un-
derestimated. This trend may be explained by the
fact that patients 5, 7, and 8, in whom the discrepan-
cy is marked, had the greatest time intervals be-
tween BUCS and renography (mean of 11.2
months), during which a deterioration in GFR had
also occurred (mean decrease in creatinine clear-
ance of 24 mllmin). The difference cannot be ac-
counted for in terms of worsening unilateral renal
artery stenosis, because the CPAH of both affected
and unaffected kidneys (Table 3) have decreased.
Although the different pairs of clearance tech-
niques have been shown to correlate well, all three
techniques may be shown to correlate closely by
deriving the multiple correlation coefficient (R)
[21] for the 17 complete sets of data detailed in
Table 1, where
R2 — + — 2r1 r2 r12
1—r2
and r1, r2, and r12 are the linear correlation coeffi-
cients derived respectively from correlations of
CPAH on the day of renography with CPAH at BUCS,
hippuran clearance with CPAH at BUCS, and hippu-
ran clearance with CPAH on the same day (equalling
0.74, 0.76, and 0.88). Thus, = 0.60, and be-
cause
p2 iL
—
Syy)IftF— (1 D2,)!(N_k 1)Iyy
where k is the number of techniques being com-
pared minus one and N is the number of sets of data
(N = 17), the correlation between the three tech-
niques has been shown to be close (F = 10.50, P <
0.01).
Clearances by individual kidneys. The PAH
clearance values for individual kidneys at the time
of BUCS and the values of hippuran clearance for
individual kidneys are presented in Table 3. On the
affected side, there is good correlation between the
two techniques (N = 14, y = 1.08x + 25, r = 0.76, P
< 0.001), as there is on the unaffected side also (N
= 16, y = 0.55x + 123, r = 0.76, P < 0.001). As in
the total clearance measurements, hippuran clear-
ances of the individual kidneys are lower than CPAH
of the individual kidneys, both on the affected side
(N = 16, paired t = —2.20; P < 0.05) and on the
unaffected side (N = 16, paired t = —1.48, P> 0.1).
Patients with renal artery stenosis. The clearance
values for patients with renal artery stenosis are in-
cluded in Tables 1 and 3, and the linear correlations
detailed in Table 4. Good correlations between the
techniques have been shown, particularly between
hippuran clearance and CPAH performed on the
same day (r = 0.96, P < 0.001). A multiple correla-
tion coefficient may also be calculated for the 11
renal artery stenosis patients with complete data in
the same manner as described above and a signifi-
cant correlation between the three established
= 0.61, F = 6.26, P < 0.05).
Mean total clearance values for the 11 patients
with complete data were 384 198, 319 222, and
800
• u
y = 0.69x + 161
N= 17
r= 0.76 p < 0.001
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Table 3. PAH and hippuran clearance by individual kidneysa
Clearance values
Patient
mi/rn in
CPAM at BUCS Hippuran clearance
Affected Unaffected Affected Unaffected
1 54 60 51 71
2 159 335 90 343
3 69 115 44 79
4 122 137 98 104
5 318 345 170 201
6 147 423 205 481
7 251 292 114 151
8 $ S 122 149
9 37 114 29 54
10 255 312 222 518
11 0 242 0 176
12 ND ND 0 131
13 94 200 100 173
14 54 231 52 158
15 102 196 123 252
16 155 193 87 100
17 218 309 172 182
18 0 247 0 185
19 ND ND 0 308
20 ND ND 166 261
21 ND ND 0 260
22 ND ND 126 126
23 ND ND 246 256
Meanvalues 127 95(N = 16) 234 99(N = 16) 96 76(N 23) 205 l20(N = 23)
a Abbreviations used are BUCS, bilateral ureteric catheterization studies; 5, urine leak at BUCS (divided values not available), and
ND, not done.
Table 4. Correlation of clearance techniques (renal artery stenosis patients)
Ordmatea Abscissa N
Regression
equation
Correlation
coefficient P
CPAH, conventional (day of renogram)
CPAH byBUCS
CPAHbyBUCS
CPAH byBUCS
on affected side
on unaffected side
Hippuran clearance
CPAH, conventional (day of renogram)
Hippuran clearance
Hippuran clearance
12
11
11
9
10
y = 0.94x + 25
y = 0.68x + 166
y = 0.69x 167
y = I .05x + 37
y = 0,58x + 111
0.96
0.77
0.78
0.75
0.81
<0.001
<0.01
<0.01
<0.02
<0.01
a BUCS is bilateral ureteric catheterization studies.
316 224 mI/mm for CPAH at BUCS, CPAH on the
day of renography, and hippuran clearance, respec-
tively. Paried t tests did not show the three groups
to be significantly different from each other. The ra-
tio of hippuran clearance to CPAH on the same day is
much closer to unity for renal artery stenosis pa-
tients (0.97 0.17) than it is for the whole group of
23 patients.
A close correlation between the techniques has
also been found when the affected and unaffected
sides in renal artery stenosis patients are considered
separately (r = 0.76 and 0.81, respectively; Table
4).
The closeness of the correlation between CPAH on
the day of renography and hippuran clearance in
renal artery stenosis patients (N = 12, r = 0.96)
may also be compared with the same correlation in
patients in this series who did not have renal artery
stenosis (N = 11, r = 0.70) by Z transformation
[22], where
z =
—
crZ1 — Z2
ando-z1—z2= +\'N1-3 N2—3
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where N1 and N2 represent, respectively, the num-
ber of patients with and without renal artery ste-
nosis. With this technique, the correlation between
the two clearance techniques has been shown to be
significantly closer for patients with renal artery ste-
nosis than it has for others in our series (Z = 2.22, P
<0.05).
Discussion
Any comparison of data derived by PAH clear-
ance and o-iodohippurate (hippuran) clearance
techniques must take into account that the two sub-
stances, even though congeners, are by no means
identical [23, 24]. Protein binding of PAH in plasma
has been estimated to range from 7 to 25%, but that
of hippuran is much higher (64 to 70%) [20]. Be-
cause PAH is 20% filtered by the glomerulus and
80% secreted by the proximal tubules [12], system-
atic differences in the clearance of the more highly
protein-bound hippuran would be expected. In-
deed, Maher and Tauxe [20] found hippuran clear-
ance to be 84% of PAH clearance, but other work-
ers [12, 25] have found a closer relationship (96%).
The present study concurs with these findings, 123J..
hippuran clearance being on average 89% of PAH
clearance, though the value for renal artery stenosis
patients is higher (97%). As Norman [24] indicates,
however, from the point of view of clinical appli-
cation, the closeness of the results obtained with
the two techniques permits the data to be inter-
preted in a similar manner in terms of kidney func-
tion. Close linear correlations between total PAH
clearance and hippuran clearance have been de-
scribed when a variety of other iodine labels for hip-
puran isotopes were used—1251-hippuran [15], 1311..
hippuran [26], and '231-hippuran [13]—and the pres-
ent study confirms this with 1231-hippuran and a
gamma camera technique (r = 0.87). If ERPF is de-
fined in terms of PAH clearance [17] and if the small
and systematic underestimate of PAH clearance
that hippuran clearance yields is borne in mind, the
latter method provides a rapid, noninvasive, and ac-
curate technique for assessing total ERPF.
In the present study, total CPAH at the time of bi-
lateral ureteric catheterization studies, which was
not significantly different from CPAH at the time of
renography, has been shown to correlate well with
hippuran clearance. What earlier studies did not
show, but this study demonstrates clearly, is that
measurements of plasma flow to individual kidneys
derived from '231-hippuran studies, as described
above, also correlate well with PAH clearance val-
ues of individual kidneys from bilateral ureteric
catheterization studies. This is true for the complete
series of patients described, and also for the pa-
tients with renal artery stenosis assessed separate-
ly. Two caveats must be applied in evaluating these
data. First, the underestimate of CPAH that hippuran
clearance gives is apparent in the measurements of
individual renal function, as it was in measurements
of total ERPF. The apparent difference, however,
may be greater than the real difference because sev-
eral months had elapsed in some cases (see patients
5, 7, 8 above) between bilateral ureteric catheteriza-
tion studies and renography, and during that time
renal function had deteriorated. Second, direct con-
firmatory evidence that the external counting meth-
ods truly reflect individual kidney function is lack-
ing, although indirect evidence is suggestive of this.
In dogs, CPAH of individual kidneys has correlated
well with both electromagnetic flowmeter measure-
ments of blood flow [27] and with 1311-hippuran
clearance [28]. In man, ratios of divided 1311-hippu-
ran clearance have been shown to parallel closely
the ratios of CPAH from divided renal function stud-
ies [29]. Such studies, together with the data pre-
sented in this paper, do not constitute proof of iden-
tity between individual hippuran clearance and
plasma flow measurements, but are suggestive that
the former are valid and clinically valuable esti-
mates of the latter.
The validation of individual ERPF measurements
by '231-hippuran renography is of particular impor-
tance in the clinical management of patients with
renal artery stenosis, because it allows serial esti-
mations of plasma flow to each kidney to be made
simply and accurately. Furthermore, the plasma
flow measurements are made under physiologic
conditions, whereas the data obtained from bilateral
ureteric catheterization studies are obtained during
a state of mannitol diuresis. But the disadvantage of
renography, as compared with bilateral ureteric
catheterization studies, is that it yields less informa-
tion with no index of urine flow, sodium excretion,
or creatinine clearance from individual kidneys.
This additional information from bilateral ureteric
catheterization studies may be very useful in reach-
ing a decision about surgery, particularly where the
results of i.v. pyelography and artenography [19]
and plasma renin and angiotensin II concentrations
from renal vein samples [30, 31] are equivocal.
Although iodine 123 is, at present, expensive and
not widely available, it has two major advantages
over iodine 131. First, because the radiation dose
per millicurrie to the kidneys of iodine 123 adminis-
tered is one fifth of that of iodine 131 [7], it enables
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activities compatible with imaging studies to be giv-
en safely. The whole body radiation dose of 1231-hip-
puran is 0.004 rad/mCi for subjects with normal re-
nal function compared with 0.02 rad/mCi for 131J.
hippuran [7]. Second, the radiation emitted by io-
dine 123 (gamma rays of energy of 159 KeV and no
beta emissions) is particularly suited to high resolu-
tion gamma camera imaging when compared with
iodine 131 (gamma rays of energy of 360 KeY and
beta rays of energy of 610 KeV).
The present study suggests that 1231-hippuran
clearance is an accurate estimate of true PAH clear-
ance, and that with 1231-hippuran renography a valid
and helpful estimate of effective renal plasma flow
to individual kidneys may be obtained. In patients
with renal artery stenosis, this technique could use-
fully replace bilateral ureteric catheterization stud-
ies if these are done simply to assess plasma flow of
the two kidneys separately.
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